Clinical trial disclosure and transparency have become important considerations in today’s biopharmaceutical landscape. A comprehensive maturity model for clinical trial disclosure and transparency offers biopharmaceutical companies a strategic tool to assess and enhance their practices in an increasingly complex regulatory environment.
This model becomes critical as the industry faces intensifying scrutiny, expanding disclosure requirements, and emerging trends that demand proactive management of clinical trial transparency. Organizations must navigate a rapidly changing landscape, from evolving global regulations to integrating new technologies.
